Advertisement
Journal Home
Search for

Volume 56, Issue 3, Pages 163-179 (March 2010)


View previous. 8 of 8

Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions

Judy W.M. Cheng, PharmD, MPH, FCCP, BCPSa, William H. Frishman, MDb, Wilbert S. Aronow, MDb

Cytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes. When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with significant clinical consequences may occur. This review discusses CYP450-mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced significant cardiovascular side effects. The principles in predicting drug interactions are also discussed.

a Arnold and Marie Schwartz College of Pharmacy and Sciences, Long Island University, Brooklyn, New York, Mt. Sinai Medical Center, New York, New York

b Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York

 Reprinted with permission from Cheng JWM, Frishman WH, Aronow WS. Updates on Cytochrome P450-Mediated Cardiovascular Drug Interactions. Am J Ther 2009;16:155-63.

PII: S0011-5029(09)00159-X

doi:10.1016/j.disamonth.2009.12.011


View previous. 8 of 8

Advertisement